Overview

Stress Echocardiography Study With Regadenoson

Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
Regadenoson is approved in the US under the brand name Lexiscan for myocardial perfusion imaging. This study will test whether regadenoson is an appropriate stress agent for stress echocardiography.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Regadenoson